PFE - Pfizer Inc.
| Previous Close | 41.47 |
| Open | 41.40 |
| Bid | 41.36 x 900 |
| Ask | 41.37 x 3200 |
| Day's Range | 41.28 - 41.71 |
| 52 Week Range | 35.32 - 46.47 |
| Volume | 14,480,519 |
| Avg. Volume | 23,362,730 |
| Market Cap | 230.15B |
| Beta (3Y Monthly) | 0.54 |
| PE Ratio (TTM) | 21.29 |
| EPS (TTM) | 1.95 |
| Earnings Date | Jul 29, 2019 - Aug 2, 2019 |
| Forward Dividend & Yield | 1.44 (3.55%) |
| Ex-Dividend Date | 2019-05-09 |
| 1y Target Est | 45.00 |
- Investopedia•42 minutes ago
Primary Drivers of the Chinese Economy
Learn about the forces driving the Chinese economy and helping the country earn money. China has the first or second largest GDP in the world but is not nearly as developed as others in the top 10.
- Motley Fool•yesterday
Better Buy: Eli Lilly vs. Pfizer
Which stock wins in a matchup between these two big drugmakers?
- Motley Fool•2 days ago
Where Will Pfizer Be in 5 Years?
The last five years were good for Pfizer shareholders. Here's how the next five could be different.
- Zacks•3 days ago
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
- Zacks•3 days ago
Dow 30 Stock Roundup: Walmart, Cisco Earnings Impress
The index enjoyed a strong week of gains after the after U.S.-China trade rhetoric cooled off to an extent.
- TheStreet.com•4 days ago
Pfizer Gains After Being Named 'Top Pick' by Credit Suisse
posted gains on Thursday after the drugmaker was named a "top pick" at Credit Suisse following a meeting the analysts had with Pfizer's management team. In a note to clients, Credit Suisse said its meeting with senior Pfizer executives boosted its confidence in both management and the prospects for new products. The move follows Credit Suisse's recent stock-price upgrade on Pfizer, in which analyst Vamil Divan raised his 12-month price target to $48 while maintaining an outperform rating.
- Zacks•4 days ago
Pfizer's Eczema Candidate Meets All Goals in Phase III Study
Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
- CNBC•4 days ago
Here are the biggest analyst calls of the day: Macy's, Pfizer, Owens Corning & more
Here are the biggest calls on Wall Street on Thursday
- CNBC•4 days ago
Stocks making the biggest moves premarket: Walmart, Pfizer, PG&E, Sony, Tesla & more
The retail giant reported adjusted quarterly profit of $1.13 per share , 11 cents a share above Wall Street forecasts. Cisco Systems CSCO — Cisco reported adjusted quarterly profit of 78 cents per share , beating the consensus estimate of 77 cents a share. The networking equipment maker's revenue also beat Street forecasts, and Cisco also gave better-than-expected current-quarter revenue guidance.
- Investor's Business Daily•4 days ago
Generic Drugs Are Stabilizing — Can They Survive An Antitrust Scandal?
The prices of generic drugs across the universe of pharmaceutical companies appeared to stabilize in the first quarter — shucking off years of broad decline, Wall Street analysts say.
- Business Wire•5 days ago
Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting
Data spans 10 therapies across 10 types of cancer
- Investor's Business Daily•5 days ago
This Dow Jones Pharma Giant Is Now A 'Top Pick' — Here's Why
Dow Jones component Pfizer could outperform Wall Street expectations for a newly approved rare heart disease treatment, an analyst said Wednesday as he named Pfizer stock a "top pick."
- Investor's Business Daily•5 days ago
Pfizer Stock Is The Biggest Pharma — But Should You Buy It?
Pfizer stock has fallen 7.1% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
- Investopedia•5 days ago
Teva Hits Fibonacci Support on Concerns Over Lawsuit
Teva Pharmaceutical shares continue to fall amid concerns about a lawsuit over alleged price fixing among generic drugmakers.
- Zacks•5 days ago
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
- Zacks•5 days ago
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
- Benzinga•5 days ago
The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
- Zacks•5 days ago
AbbVie Settles Humira Litigation With Boehringer Ingelheim
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
- Reuters•5 days ago
Pfizer's atopic dermatitis treatment meets goals in late-stage study
Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday. Abrocitinib, which belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as Janus kinases, achieved statistically significant improvement in clearing the skin of patients as compared to placebo. The results of the study, which tested two doses of the drug in 387 patients, showed abrocitinib was consistently well-tolerated, Pfizer said.
- GlobeNewswire•5 days ago
Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
- Reuters•5 days ago
Pfizer's dermatitis treatment meets main goals of late-stage study
Pfizer Inc's dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday. The study tested two doses of the drug, abrocitinib, in 387 patients with atopic dermatitis, the company said. Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects.
- Business Wire•5 days ago
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
- PR Newswire•6 days ago
FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
DARMSTADT, Germany and NEW YORK , May 15, 2019 /PRNewswire/ -- Not intended for US, Canada and UK-based media BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA for first-line ...
- PR Newswire•6 days ago
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Not intended for UK-based media ROCKLAND, Mass. and NEW YORK , May 14, 2019 /PRNewswire/ -- BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatment of patients ...
